KALA BIO, Inc.
Stock exchange listing-rule deficiency notice (8-K Item 3.01)
The company reported in a Form 8-K (Item 3.01) filed on 28 Aug 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.
More details →Stock exchange listing-rule deficiency notice (8-K Item 3.01)
The company reported in a Form 8-K (Item 3.01) filed on 23 Jan 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.
More details →Stock exchange listing-rule deficiency notice (8-K Item 3.01)
The company reported in a Form 8-K (Item 3.01) filed on 12 Nov 2025 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.
More details →Annual report filed late (NT 10-K)
The company filed Form NT 10-K with the SEC on 31 Mar 2026, notifying investors that its annual report would be late. A late annual report can point to accounting or audit problems, though the reason is sometimes routine.
More details →Quarterly report filed late (NT 10-Q)
The company filed Form NT 10-Q with the SEC on 14 Aug 2026, notifying investors that its quarterly report would be late. Late filings can point to accounting or business problems, though the reason is sometimes routine.
More details →Change of auditor (8-K Item 4.01)
The company reported a change of its independent auditor in a Form 8-K (Item 4.01) filed on 29 Dec 2025. Auditor changes are often routine (rotation, cost, mergers), but can follow disagreements over accounting.
More details →Change of auditor (8-K Item 4.01)
The company reported a change of its independent auditor in a Form 8-K (Item 4.01) filed on 16 Dec 2025. Auditor changes are often routine (rotation, cost, mergers), but can follow disagreements over accounting.
More details →Quarterly report filed late (NT 10-Q)
The company filed Form NT 10-Q with the SEC on 14 Nov 2025, notifying investors that its quarterly report would be late. Late filings can point to accounting or business problems, though the reason is sometimes routine.
More details →KALA BIO, Inc. — Overview & Financial Snapshot
KALA BIO, Inc. (NasdaqCM: KALA) is a Healthcare company, ranked #2,686 of 6,774 companies globally and #928 of 4,000 in United States on PositoAI, with a Positivity Score of 21,242. Its market capitalisation is ₹33.86 Cr ($3.59M), P/E ratio is -0.0 and P/B ratio is 0.40. It currently has 3 active red flags (PosiRed) and 5 yellow flags (PosiYellow, 10/10 points) on record.
For financial statements, ratio trends and score history, Go Deep →